A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions

ClinicalTrials.gov ID: NCT02395042

Public ClinicalTrials.gov record NCT02395042. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a safety and efficacy study of LiRIS® in females with interstitial cystitis with Hunner's lesions.

Study identification

NCT ID: NCT02395042
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Allergan; Industry
Enrollment: 59 participants

Conditions and interventions

Conditions

Interventions

LiRIS® Drug
LiRIS Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 15, 2015 (Actual)
Primary completion: Jun 29, 2017 (Actual)
Completion: Nov 20, 2017 (Actual)
Last update posted: Oct 5, 2018

2015 – 2017

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
Tri Valley Urology Medical Group	Murrieta	California	92562	—
Sutter Institute for Medical Research	Vacaville	California	95688	—
Women's Health Specialty Care	Farmington	Connecticut	06032	—
Atlanta Medical Research Institute	Alpharetta	Georgia	30005	—
Anne Arundel Urology, P.A.	Annapolis	Maryland	21401	—
Chesapeake Urology Research Associates	Baltimore	Maryland	21237	—
Beyer Research	Kalamazoo	Michigan	49009	—
Beaumont Health System	Royal Oak	Michigan	48073	—
Washington University School of Medicine Department of Surgery	St Louis	Missouri	63110	—
Western New York Urology Associates, LLC	Cheektowaga	New York	14214	—
McKay Urology	Charlotte	North Carolina	28207	—
Eastern Urological Associates, PA	Greenville	North Carolina	27834	—
Wake Forest Baptist Health	Winston-Salem	North Carolina	27103	—
MetroHealth System/Center for Advanced Gynecology	Cleveland	Ohio	44109	—
Philadelphia Urosurgical Associates	Philadelphia	Pennsylvania	19107	—
University of Washington	Seattle	Washington	98195	—
Aurora Health Care	West Allis	Wisconsin	53227	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02395042, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2018 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02395042 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →